Geron Corporation (GERN)
News
| May 25 | current long positions: $GNOM @2.95 $GERN @1.71 $AAPL @554.62 $BGU @68.51 $PCS @11.15 $TNA @33.90 $THLD @2.28 $YOKU @25.66 $ANR @17.16 by kotekaz |
| May 24 | $GERN link to court materials and some discussion http://stks.co/3ynx by BrantleyFoster |
| May 23 | long $GERN adding to my position at support @1.39. Mean price now @1.71, patience on this one, now in phase II cell lung cancer trial. by kotekaz |
| May 22 | This Just In: More Upgrades and Downgrades Fool |
| May 21 | $GERN what is this court ruling in 5 days on $GERN everyone is talking about??? by BiopharmaPro |
| May 18 | GERON CORP Files SEC form 8-K, Change in Directors or Principal Officers, Amendments ... |
| May 17 | Osiris Wins Canadian Approval for First Stem-Cell Therapy |
| May 16 | nice midday comeback for $GERN by swingtrades99 |
| May 11 | $gern analysts 12-month price forecasts of 3.00 .The median estimate represents a +102.02% increase from last price 1.49. that's double play by GOTUBRAD |
| May 11 | into a significant long holding of $GERN at 1.52 by swingtrades99 |
| May 09 | Small Biotechs Like Aastrom Biosciences and Geron Likely to Benefit From New Patent S... |
| May 07 | GERON CORP Files SEC form 10-Q, Quarterly Report |
Profile
Exchange: NASDAQGM Sector: Healthcare Industry: Biotechnology
Geron Corporation is a biotechnology company located in Menlo Park, California that specializes in developing and commercialization of products in three specific areas: 1) therapeutic products for cancer that inhibit telomerase; 2) pharmaceuticals that activate telomerase in tissues impacted by cell aging, injury or degenerative diseases; and 3) cell-based therapies derived from human embryonic stem cells for treatment of various chronic diseases.
1 Year Total Return Performance
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Geron Corporation is down 68.09% over the last year vs S&P 500 Total Return up 1.18%, Verastem up 0.00%, and Aastrom Biosciences down 33.87%.
- GERN Total Returns
- ^SPXTR Total Returns
- VSTM Total Returns
- ASTM Total Returns
Fundamentals
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Cash Flow Statement View Statement
You may also be interested in these GERN related companies
Pro Strategies Featuring GERN
Did Geron Corporation make it into our Pro Portfolio Strategies?
GERN Charts
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Other GERN Resources
- Wiki Page
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership MSN Money
- SEC Filings SEC
- Technical Charts Chart.ly
- Trading Ideas Benzinga
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| GERN | 1.42 | +0.03 | +2.16% | 187.81M |
| GEOY | 20.39 | +1.29 | +6.75% | 453.47M |
| FVE | 3.05 | -0.03 | -0.97% | 146.10M |
| FVD | 16.26 | -0.02 | -0.12% | |
| FURX | 19.10 | +0.88 | +4.83% | 190.04M |
| FUR | 10.30 | -0.10 | -0.96% | 340.42M |
| FUND | 6.26 | +0.06 | +0.97% | |
| FUN | 26.60 | +0.13 | +0.49% | 1.473B |
| FULT | 10.24 | -0.04 | -0.39% | 2.051B |
| FSYS | 15.10 | -0.24 | -1.56% | 302.15M |
